Manufacture and sell nuclear medicine calibration and reference standards for SPECT and PET imaging. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 8% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 2.6× for every dollar of annual revenue.
No analyst target is on record for this company.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades 41% below its peak. The market has trimmed its expectations for the company.
Sales run at $13.1M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 11 buys and 1 sell. Management buying with its own money is usually read as a good sign.
A loss of $908K against $13.1M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.07. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.